Biotech deal activity surges in year-end 2025 window The final week of 2025 and opening days of 2026 delivered over

Sublicense royalties have become an important feature in pharmaceutical royalty financing deals, especially as biotech firms and pharma companies seek

In the basement of a nondescript office building in South San Francisco, the fluorescent lights still hummed over empty lab

Six thoughtful (and slightly cheeky) resolutions for biotech investors, executives, and scientists to make 2026 a breakthrough year.

What Is a Revenue Interest Purchase and Sale Agreement? A Revenue Interest Purchase and Sale Agreement is a contractual financing

In restructuring parlance, a stalking horse bid is an initial binding offer on a bankrupt debtor's assets, made by a chosen buyer, that sets the floor price for an auction.

The pharmaceutical industry's computational infrastructure is undergoing its most dramatic transformation in decades. NVIDIA's Blackwell architecture,

The final full week of 2025 delivered over $10.5 billion in biotech and pharma transactions despite the holiday lull.

The pharmaceutical industry runs on promises. Drug companies promise to pay royalties when products succeed. Acquirers promise additional payments if

A record 161 biotechnology companies traded at negative enterprise value in mid-2025, representing over $5 billion in trapped capital where shareholders hold claims on cash that market prices say is worth less than nothing.